United States Patent 11,324,741: Scope of Claims, Claim-by-Claim Coverage, and Competitive Patent Landscape (Insulin Resistance + Naltrexone/Bupropion Combination)
What is the patented subject matter in US 11,324,741?
US Drug Patent 11,324,741 is directed to methods of improving metabolic markers in a person identified as having a need for such improvement, using a combination of naltrexone (or pharmaceutically acceptable salts) plus bupropion (or pharmaceutically acceptable salts).
The independent core of the claim set is a dose-range combination intended to produce improvements in insulin resistance markers and lipid and glycemic endpoints that are greater than expected from weight loss alone or greater than expected from each monotherapy alone.
Key claimed act
- Administer naltrexone: about 4 mg to about 50 mg per day
- Administer bupropion: about 100 mg to about 600 mg per day
- Target effect is improvement in markers, with synergy framed by expectation comparisons.
Key framing language
- For insulin resistance markers: improvement is greater than expected from weight loss alone (claim 1)
- For fasting blood glucose: improvement is significantly greater than expected from naltrexone or bupropion alone (claim 5)
- For triglycerides: improvement is greater than expected from naltrexone or bupropion alone (claim 14)
How broad is the claim scope on dose and endpoints?
Dose ranges
The combination is broad on both components:
| Component |
Claimed daily range |
Typical “specific embodiment” values in dependent claims |
| Naltrexone (or salt) |
4 mg to 50 mg |
32 mg (claims 2, 6, 11) |
| Bupropion (or salt) |
100 mg to 600 mg |
400 mg (claims 2, 6, 11) |
This range structure creates two practical coverage layers:
- Generic dose-covering coverage (4–50 mg naltrexone and 100–600 mg bupropion)
- Narrower “fixed-dose” embodiments explicitly called out at 32 mg + 400 mg
Endpoint coverage
The claim set covers multiple metabolic domains:
- Insulin resistance markers (claim 1)
- Fasting blood glucose (claims 5, 9)
- Triglyceride and/or HDL cholesterol (claims 10, 14, 15)
- Sex-specific HDL thresholds (claims 17–18)
| Domain |
Claims |
Outcome thresholds / directionality |
| Insulin resistance markers |
1 |
Improvement > expected from weight loss alone |
| Fasting glucose |
5, 9 |
Claim 9: reduced to < about 110 mg/dL |
| Triglycerides |
10, 14, 16 |
Claim 16: reduced to < about 150 mg/dL |
| HDL cholesterol |
10, 15, 17–18 |
Male > about 40 mg/dL; Female > about 50 mg/dL |
What is the claim-by-claim coverage and how does it narrow in dependent claims?
Claim 1: Independent method claim for insulin resistance markers
Claim 1 is the broadest method frame for insulin resistance markers:
- Combination dosing:
- naltrexone 4–50 mg/day
- bupropion 100–600 mg/day
- Population: “a person” identified/diagnosed as needing improvement
- Effect limitation:
- improvement in markers of insulin resistance is greater than expected from weight loss alone
Practical scope implications
- The claim is not limited to a particular obesity status wording, but it uses weight-loss-only expectation as a benchmark.
- This makes the evidentiary requirement in enforcement revolve around showing the metabolic marker improvement exceeds what would be attributable to weight loss.
Claim 2: Fixed-dose embodiment
Claim 2 narrows Claim 1 to a specific dosing pair:
- bupropion about 400 mg/day
- naltrexone about 32 mg/day
Claim 3: Single dosage form
Claim 3 narrows Claim 1 by requiring:
- naltrexone + bupropion administered together in a single dosage form
This is narrower than “concurrent administration” (it is specifically “single dosage form”).
Claim 4: Sustained-release for both components
Claim 4 narrows Claim 1 by requiring:
- naltrexone in sustained-release form
- bupropion in sustained-release form
This provides formulation-dependent coverage; if a competitor uses immediate-release or different release profiles, Claim 4 may not read on those embodiments.
Claim 5: Independent method claim for fasting blood glucose
Claim 5 is similar in dosing scope but changes the endpoint and the “expected improvement” comparator:
- naltrexone 4–50 mg/day
- bupropion 100–600 mg/day
- effect limitation: improvement in fasting blood glucose is significantly greater than expected from naltrexone or bupropion alone
This sets up a synergy framing relative to each monotherapy.
Claim 6: Fixed-dose embodiment
Claim 6 narrows Claim 5:
- bupropion about 400 mg/day
- naltrexone about 32 mg/day
Claim 7: Single dosage form
Claim 7 requires:
- both administered together in a single dosage form
Claim 8: Sustained-release for both
Claim 8 requires:
- naltrexone sustained-release
- bupropion sustained-release
Claim 9: Specific fasting glucose threshold
Claim 9 narrows Claim 5 to a measurable clinical endpoint:
- fasting blood glucose reduced to less than about 110 mg/dL
This is an additional numeric floor/ceiling that can materially affect infringement analysis for methods depending on achieved outcomes.
Claim 10: Independent method claim for triglycerides and/or HDL
Claim 10 expands metabolic coverage beyond glucose:
- dosing ranges:
- naltrexone 4–50 mg/day
- bupropion 100–600 mg/day
- endpoint framing is broader: “improving triglyceride levels or high-density cholesterol levels”
Notably:
- Claim 10 uses “or,” which creates two possible infringement routes:
- triglycerides improvement
- HDL cholesterol improvement
It does not, on its face, include a “greater than expected” synergy qualifier.
Claim 11: Fixed-dose embodiment
Claim 11:
- bupropion about 400 mg/day
- naltrexone about 32 mg/day
Claim 12: Single dosage form
Claim 12:
- naltrexone and bupropion administered together in a single dosage form
Claim 13: Sustained-release for both
Claim 13:
- naltrexone sustained-release
- bupropion sustained-release
Claim 14: Triglycerides synergy qualifier
Claim 14 depends on Claim 10 but adds:
- method improves triglyceride levels
- improvement is greater than expected from naltrexone or bupropion alone
This is the triglyceride-specific synergy frame.
Claim 15: HDL improvement
Claim 15 depends on Claim 10:
- method improves high-density cholesterol levels
No numeric threshold or synergy qualifier in Claim 15 itself.
Claim 16: Specific triglyceride threshold
Claim 16:
- triglyceride levels reduced to less than about 150 mg/dL
Claim 17: Male HDL threshold
Claim 17:
- male
- HDL increased to more than about 40 mg/dL
Claim 18: Female HDL threshold
Claim 18:
- female
- HDL increased to more than about 50 mg/dL
These sex-specific thresholds add constraining clinical parameters but also define clear metric targets.
Where is the “real” breadth: what parts map to product-competitive design choices?
Broadest commercial design targets
The claim set most strongly captures competitors that do any of the following:
- Use the naltrexone + bupropion combination at daily doses within range
- naltrexone 4–50 mg/day and bupropion 100–600 mg/day
- Aim at insulin resistance and/or fasting glucose and/or triglycerides and HDL
- Seek outcome improvements beyond monotherapy or weight-loss-only expectations, especially for:
- insulin resistance markers (Claim 1)
- fasting glucose (Claim 5)
- triglycerides (Claim 14)
Narrowest commercial design “escape hatches”
The dependent claims create practical carve-outs for certain formulation and administration strategies:
- Separate dosage forms
- Claims 3, 7, 12 require a single dosage form. If administered separately, those dependent claims are avoided.
- Release profile mismatch
- Claims 4, 8, 13 require both components in sustained-release form.
- Outcome-based non-achievement
- Threshold-dependent claims can be designed around by not achieving the thresholds (claims 9, 16, 17, 18).
- However, method claims often still risk coverage if clinical improvement is shown for the claimed endpoints even without hitting exact thresholds, depending on how a tribunal construes the “reduced to less than” or “increased to more than” limits.
How does the “greater than expected” language affect enforceability and landscape risk?
The claims use two expectation benchmarks:
- Expected from weight loss alone (Claim 1)
- Expected from naltrexone or bupropion alone (Claims 5 and 14)
This design affects the competitive landscape because it shifts dispute focus away from dose selection alone and toward comparative clinical performance.
Competitive exposure areas
- If a challenger markets a combination in the same dose range but frames only as weight-loss therapy, Claim 1 creates risk if insulin resistance markers improve beyond what weight loss alone would predict.
- If a challenger uses the combination but clinical outcomes do not demonstrate synergy relative to monotherapy, Claims 5 and 14 could be harder to enforce while Claim 10 may still create risk for triglyceride/HDL improvement depending on which endpoint is pursued.
Patent landscape: what this implies for competitors (without relying on uncited record details)
A full landscape normally requires bibliographic and prosecution data for US 11,324,741 (assignee, earliest priority, claim construction notes, related continuation/divisional families, and citing/cited references). That information is not included in the input.
What can be stated directly from the claim text is the structural competitive footprint:
1) Combination-of-known-actives method claim
The patent is not claiming a novel molecular entity per the provided text. It is a method of improving outcomes with a defined dosing range combination.
Implication:
- Competitors can face risk even if they use known ingredients because the claims focus on:
- dose range
- endpoint improvements
- comparative improvement framing
- formulation/administration constraints in dependents
2) Multi-endpoint strategy increases capture probability
By covering insulin resistance markers, fasting glucose, triglycerides, and HDL cholesterol, the patent:
- supports multiple clinical endpoints in a single development program
- reduces the ability for competitors to “pick a different endpoint” to avoid the claim set
3) Dependent claims create multiple theory of infringement
Competitors can be exposed through:
- dosing within ranges (independent claims)
- fixed-dose embodiments (claims 2, 6, 11)
- single dosage form (claims 3, 7, 12)
- sustained-release (claims 4, 8, 13)
- thresholds for fasting glucose, triglycerides, and sex-specific HDL (claims 9, 16, 17, 18)
Key takeaways
- US 11,324,741 covers methods using naltrexone (4–50 mg/day) plus bupropion (100–600 mg/day) to improve insulin resistance markers, fasting glucose, and lipid endpoints (triglycerides and/or HDL).
- Synergy framing is explicit:
- Claim 1 uses greater than expected from weight loss alone
- Claims 5 and 14 use significantly/greater than expected vs naltrexone or bupropion alone
- Dependent claims create formulation and administration hooks:
- single dosage form (claims 3, 7, 12)
- sustained-release for both actives (claims 4, 8, 13)
- Outcome thresholds are a separate risk lever:
- fasting glucose < about 110 mg/dL (claim 9)
- triglycerides < about 150 mg/dL (claim 16)
- HDL targets differ by sex (claims 17–18)
- Competitive risk is highest for programs that:
- dose within the claimed ranges,
- pursue these endpoints,
- and can show comparative clinical improvement beyond weight loss or monotherapy.
FAQs
-
Does US 11,324,741 claim a specific fixed-dose product?
Yes. Dependent claims recite bupropion about 400 mg/day with naltrexone about 32 mg/day (claims 2, 6, 11).
-
Is single dosage form required for all claims?
No. Single dosage form is required only in dependent claims 3, 7, and 12.
-
Are sustained-release formulations mandatory?
No. Sustained-release for both actives is limited to dependent claims 4, 8, and 13.
-
What endpoint is explicitly tied to a fasting glucose threshold?
Claim 9: fasting blood glucose reduced to less than about 110 mg/dL.
-
How are HDL targets specified?
HDL is capped by sex-specific increases:
- Male: more than about 40 mg/dL (claim 17)
- Female: more than about 50 mg/dL (claim 18)
References
No sources were provided in the input other than the claim text itself, and no verifiable bibliographic record for US 11,324,741 is included. Therefore, there are no citable references to list.
